Temozolomide Treatment in Aggressive Pituitary Tumors and Pituitary Carcinomas: A French Multicenter Experience

• DOI: 10.1210/jc.2010-0644
• Publication Date: 2010-07-22T01:33:57Z
• Authors: Gérald Raverot; Nathalie Sturm; Florence de Fraipont; Marie Muller; Sylvie Salenave; Philippe Caron; Olivier Chabre; Philippe Chanson; Christine Cortet-...; Richard Assaker; Henry Dufour; Stephan Gaillard; Patrick François; Emmanuel Jouanneau; Jean-Guy Passagia; Michèle Bernier; Aurélie Cornélius; Dominique Figarel...; Jacqueline Trouillas; Françoise Borson-...; Thierry Brue
• Keywords: Temozolomide; Carboplatin; Pituitary Tumors

To date only 18 patients with aggressive pituitary tumors or carcinomas treated temozolomide have been reported. Increased expression of O6-methylguanine-DNA-methyltranferase (MGMT) has suggested to predict resistance temozolomide.The objective the study was describe antitumoral efficacy and toxicity in evaluate possible prognostic value MGMT promoter methylation protein expression.Eight patients, five (three prolactin (PRL) two ACTH) three (one PRL ACTH), all administered orally for four 24 cycles, were included our French multicenter study.MGMT assessed by immunohistochemistry pyrosequencing.Three eight (two ACTH adenomas one carcinoma) responded as demonstrated significant tumor shrinkage reduced hormone secretion. Three cycles sufficient identify treatment-responsive patients. Additional did not improve treatment those responding, even when associated carboplatin vepeside. tumoral response because it positive responder negative nonresponders. Similarly, seven tumors) clinical response. Toxicity remained mild patients.Temozolomide may be an effective option some carcinomas. Response a trial seems responders more reliable than patient status.